Esperion Therapeutics, Inc. (ESPR)

Esperion Therapeutics’ first fiscal quarter of 2026 results missed revenue expectations, as revenue of $80.1 million trailed the $84.5 million estimate (-5.2%), even as the top line rose 23.2% year over year to roughly $80 million (up from $65.0 million a year ago) when it reported on May 8, 2026. The quarter produced an EPS loss of -$0.10, while operating income was a loss of about $6.6 million, leaving operating margin at roughly -8%. Net income improved year over year to a loss of about $25 million (up 37.7% from a loss of -$40.5 million a year ago). Cash generation remained negative, with negative operating cash flow of roughly $27.7 million. For the next period, consensus calls for EPS of -$0.02 on revenue of $92.5 million.